Remove 2003 Remove Communication Remove Dosage
article thumbnail

Paediatric oral compounding: expert insights from a global study

Hospital Pharmacy Europe

Furthermore, it is imperative to raise physician awareness of the practice of compounding and ensure communication between physicians and pharmacists to achieve accurate paediatric prescribing. Some APIs are only available as coated or modified release dosage forms, adding to the complexity of compounding.

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

The FDA Law Blog

The closest FDA has come is in a 2003 preamble noting that patents that claim finished dosage forms—which can include “metered aerosols, capsules, metered sprays, gels, and pre-filled drug delivery systems”—should be listed in the Orange Book, suggesting that a patent that claims both the drug substance and the delivery device should be listed.

FDA 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Naltrexone interactions to avoid

The Checkup by Singlecare

Communicating openly with your healthcare team about all medical conditions you have and medications you take is the best way to identify potential naltrexone interactions. While some interactions require close monitoring or a dosage adjustment, other medications aren’t safe to combine and shouldn’t be taken together.

article thumbnail

Metronidazole interactions to avoid

The Checkup by Singlecare

Propylene glycol is primarily limited to injectable and rectal dosage forms of some medications, including diazepam, digoxin, lorazepam, phenobarbital, phenytoin, and sulfamethoxazole. Alcohol may be contained in many pharmaceutical products, like elixirs.

Dosage 52
article thumbnail

SPuMoNI: Enhancing Pharma Data Quality through Smart Technologies

ISPE

End-to-End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation.” 5 (2003): 395–413. You may unsubscribe from these ISPE communications at any time. Lakerveld, B. Benyahia, P. Barton, R. Braatz, et al. Angewandte Chemie International Edition in English 52, no. Microsoft.com.

article thumbnail

CMC Requirements for New Drug Registration in Latin America

ISPE

The information required in these declarations include product information (name, strength, dosage form), manufacturer, packager and license holder, and drug product manufacturing site name and country. In Chile, it is required to include specific tests in the local drug product specification, depending on the dosage form.